In 2004 he began postdoctoral work at the University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, investigating the role of
EBV lytic infection and the role of HDM - 2 inhibitors in myeloma and lymphoma treatment.
We performed systematic quantitative analyses of temporal changes in host and
EBV proteins during
lytic replication to gain insights into virus - host interactions, using conditional Burkitt lymphoma models of type I and II
EBV infection.